ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc. price
0% Past Week
Market Cap
502.88M
Day’s Range
52W Range
Volume (3M)
1.87M
Price-Earnings Ratio
-1.22
Revenue
192K
Allogene Therapeutics Inc. Latest News



About Allogene Therapeutics Inc.
Allogene Therapeutics is a US-based, clinical-stage, biotechnology healthcare company focussed on developing cancer treatments. The firm’s research is based on the development of allogeneic chimeric antigen receptor T-cell therapies. Founded in 2017, Allogene Therapeutics is based in San Francisco, California and is working to provide therapeutic treatments to patients worldwide who are living with hematologic cancers and solid tumours.
Allogene trades on the NASDAQ GS with the ticker ALLO. The company launched its IPO in October 2018 with what was generally considered to be one of the biggest and most lucrative public offerings in over a decade, raising $324m and resulting in a market value of over $2bn. ALLO stock rose more than 30% on its first day of public trading.
The company’s successful IPO was no doubt fuelled by previous well-publicised successes. In April 2018, the firm acquired Pfizer’s allogeneic CAR T portfolio and closed its Series A round of venture capital financing, raising $300m from a premium investment consortium made up of some of the leading names in biotechnology, such as Gilead and Pfizer.
Are you considering investing in this instrument? Get news and updates on price changes by adding ATT stock to your eToro watchlist now.
Show MoreDavid D. Chang, MD, PhD
CEO
361
Employees
2017
Founded
South San Francisco, California, US
HQ
Upcoming Events
1
NOV
REPORTS
Allogene Therapeutics Inc. Q3 2023 earnings report is expected to be released after market open
Consensus
Moderate Buy
Price Target
28.00
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
55
High
Industry
Avg. 45
45
Environment
60
Social
53
Governance
People Also Bought
- OCUL Ocular Therapeutix Inc -9.21%
- PTGX Protagonist Therapeutics Inc -1.79%
- MCRB Seres Therapeutics Inc -2.91%
TWST Twist Bioscience Corporation 1.74%
RLAY Relay Therapeutics Inc. -1.72%